AU2021369942A1 - Compositions and methods for treatment of autism spectrum disorder - Google Patents
Compositions and methods for treatment of autism spectrum disorder Download PDFInfo
- Publication number
- AU2021369942A1 AU2021369942A1 AU2021369942A AU2021369942A AU2021369942A1 AU 2021369942 A1 AU2021369942 A1 AU 2021369942A1 AU 2021369942 A AU2021369942 A AU 2021369942A AU 2021369942 A AU2021369942 A AU 2021369942A AU 2021369942 A1 AU2021369942 A1 AU 2021369942A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- combination
- oil
- cbd
- thc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 159
- 208000029560 autism spectrum disease Diseases 0.000 title claims description 62
- 238000011282 treatment Methods 0.000 title claims description 30
- 238000000034 method Methods 0.000 title claims description 24
- 150000003505 terpenes Chemical class 0.000 claims abstract description 107
- 235000007586 terpenes Nutrition 0.000 claims abstract description 105
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims abstract description 88
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 80
- 229930003827 cannabinoid Natural products 0.000 claims abstract description 76
- 239000003557 cannabinoid Substances 0.000 claims abstract description 76
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims abstract description 44
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims abstract description 44
- 229930007744 linalool Natural products 0.000 claims abstract description 44
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 claims abstract description 42
- 235000001510 limonene Nutrition 0.000 claims abstract description 40
- 229940087305 limonene Drugs 0.000 claims abstract description 40
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 claims abstract description 9
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 claims abstract description 8
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 claims abstract description 8
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 97
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 97
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 97
- 229950011318 cannabidiol Drugs 0.000 claims description 97
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 97
- 229960004242 dronabinol Drugs 0.000 claims description 83
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 75
- 229940117948 caryophyllene Drugs 0.000 claims description 40
- 208000024891 symptom Diseases 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000003826 tablet Substances 0.000 claims description 19
- 239000002199 base oil Substances 0.000 claims description 17
- 238000004891 communication Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 claims description 12
- OIVPAQDCMDYIIL-UHFFFAOYSA-N 5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-7-propylchromene-6-carboxylic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCC)C(C(O)=O)=C2O OIVPAQDCMDYIIL-UHFFFAOYSA-N 0.000 claims description 12
- ZLYNXDIDWUWASO-UHFFFAOYSA-N 6,6,9-trimethyl-3-pentyl-8,10-dihydro-7h-benzo[c]chromene-1,9,10-triol Chemical compound CC1(C)OC2=CC(CCCCC)=CC(O)=C2C2=C1CCC(C)(O)C2O ZLYNXDIDWUWASO-UHFFFAOYSA-N 0.000 claims description 12
- NAGBBYZBIQVPIQ-UHFFFAOYSA-N 6-methyl-3-pentyl-9-prop-1-en-2-yldibenzofuran-1-ol Chemical compound C1=CC(C(C)=C)=C2C3=C(O)C=C(CCCCC)C=C3OC2=C1C NAGBBYZBIQVPIQ-UHFFFAOYSA-N 0.000 claims description 12
- VNGQMWZHHNCMLQ-UHFFFAOYSA-N 6-methyl-3-pentyl-9-propan-2-yldibenzofuran-1-ol Chemical compound C1=CC(C(C)C)=C2C3=C(O)C=C(CCCCC)C=C3OC2=C1C VNGQMWZHHNCMLQ-UHFFFAOYSA-N 0.000 claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 208000013403 hyperactivity Diseases 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000002417 nutraceutical Substances 0.000 claims description 10
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 claims description 9
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 claims description 7
- OQCOBNKTUMOOHJ-RSGMMRJUSA-N (5as,6s,9r,9ar)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-2-carboxylic acid Chemical compound C1=2C(O)=C(C(O)=O)C(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O OQCOBNKTUMOOHJ-RSGMMRJUSA-N 0.000 claims description 6
- HJMCQDCJBFTRPX-RSGMMRJUSA-N (5as,6s,9r,9ar)-1,6-dihydroxy-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-4-carboxylic acid Chemical compound [C@H]1([C@@H](CC[C@@]2(O)C)C(C)=C)[C@@H]2Oc2c(C(O)=O)c(CCCCC)cc(O)c21 HJMCQDCJBFTRPX-RSGMMRJUSA-N 0.000 claims description 6
- RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 claims description 6
- IQSYWEWTWDEVNO-ZIAGYGMSSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCC)C(C(O)=O)=C1O IQSYWEWTWDEVNO-ZIAGYGMSSA-N 0.000 claims description 6
- TZGCTXUTNDNTTE-DYZHCLJRSA-N (6ar,9s,10s,10ar)-6,6,9-trimethyl-3-pentyl-7,8,10,10a-tetrahydro-6ah-benzo[c]chromene-1,9,10-triol Chemical compound O[C@@H]1[C@@](C)(O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 TZGCTXUTNDNTTE-DYZHCLJRSA-N 0.000 claims description 6
- YEDIZIGYIMTZKP-UHFFFAOYSA-N 1-methoxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene Chemical compound C1=C(C)C=C2C3=C(OC)C=C(CCCCC)C=C3OC(C)(C)C2=C1 YEDIZIGYIMTZKP-UHFFFAOYSA-N 0.000 claims description 6
- CZXWOKHVLNYAHI-LSDHHAIUSA-N 2,4-dihydroxy-3-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-propylbenzoic acid Chemical compound OC1=C(C(O)=O)C(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 CZXWOKHVLNYAHI-LSDHHAIUSA-N 0.000 claims description 6
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 claims description 6
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 claims description 6
- XWIWWMIPMYDFOV-UHFFFAOYSA-N 3,6,6,9-tetramethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2OC(C)(C)C3=CC=C(C)C=C3C2=C1O XWIWWMIPMYDFOV-UHFFFAOYSA-N 0.000 claims description 6
- FAVCTJGKHFHFHJ-GXDHUFHOSA-N 3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-propylbenzoic acid Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O FAVCTJGKHFHFHJ-GXDHUFHOSA-N 0.000 claims description 6
- VAFRUJRAAHLCFZ-GHRIWEEISA-N 3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2-hydroxy-4-methoxy-6-pentylbenzoic acid Chemical compound CCCCCC1=CC(OC)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O VAFRUJRAAHLCFZ-GHRIWEEISA-N 0.000 claims description 6
- GGVVJZIANMUEJO-UHFFFAOYSA-N 3-butyl-6,6,9-trimethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCC)C=C3OC(C)(C)C2=C1 GGVVJZIANMUEJO-UHFFFAOYSA-N 0.000 claims description 6
- QUYCDNSZSMEFBQ-UHFFFAOYSA-N 3-ethyl-6,6,9-trimethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CC)C=C3OC(C)(C)C2=C1 QUYCDNSZSMEFBQ-UHFFFAOYSA-N 0.000 claims description 6
- IPGGELGANIXRSX-RBUKOAKNSA-N 3-methoxy-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenol Chemical compound COC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 IPGGELGANIXRSX-RBUKOAKNSA-N 0.000 claims description 6
- IPGGELGANIXRSX-UHFFFAOYSA-N Cannabidiol monomethyl ether Natural products COC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 IPGGELGANIXRSX-UHFFFAOYSA-N 0.000 claims description 6
- KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 claims description 6
- NHZMSIOYBVIOAF-UHFFFAOYSA-N cannabichromanone A Natural products O=C1C(CCC(C)=O)C(C)(C)OC2=CC(CCCCC)=CC(O)=C21 NHZMSIOYBVIOAF-UHFFFAOYSA-N 0.000 claims description 6
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 claims description 6
- VAFRUJRAAHLCFZ-UHFFFAOYSA-N cannabigerolic acid monomethyl ether Natural products CCCCCC1=CC(OC)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O VAFRUJRAAHLCFZ-UHFFFAOYSA-N 0.000 claims description 6
- JVOHLEIRDMVLHS-UHFFFAOYSA-N ctk8i6127 Chemical compound C1=2C(O)=C(C(O)=O)C(CCCCC)=CC=2OC2(C)CCC3C(C)(C)C1C23 JVOHLEIRDMVLHS-UHFFFAOYSA-N 0.000 claims description 6
- 239000004006 olive oil Substances 0.000 claims description 6
- 235000008390 olive oil Nutrition 0.000 claims description 6
- GKVOVXWEBSQJPA-UONOGXRCSA-N 5-methyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound CC(=C)[C@@H]1CCC(C)=C[C@H]1C1=C(O)C=C(C)C=C1O GKVOVXWEBSQJPA-UONOGXRCSA-N 0.000 claims description 5
- 235000013871 bee wax Nutrition 0.000 claims description 5
- 239000012166 beeswax Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003240 coconut oil Substances 0.000 claims description 5
- 235000019864 coconut oil Nutrition 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- 239000008297 liquid dosage form Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- WBRXESQKGXYDOL-DLBZAZTESA-N 5-butyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound OC1=CC(CCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WBRXESQKGXYDOL-DLBZAZTESA-N 0.000 claims description 4
- GGHRHCGOMWNLCE-VQTJNVASSA-N 5-heptyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound OC1=CC(CCCCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 GGHRHCGOMWNLCE-VQTJNVASSA-N 0.000 claims description 4
- 241001133760 Acoelorraphe Species 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 239000010478 argan oil Substances 0.000 claims description 4
- 239000008163 avocado oil Substances 0.000 claims description 4
- 235000021302 avocado oil Nutrition 0.000 claims description 4
- 239000000828 canola oil Substances 0.000 claims description 4
- 235000019519 canola oil Nutrition 0.000 claims description 4
- 239000008169 grapeseed oil Substances 0.000 claims description 4
- 239000010460 hemp oil Substances 0.000 claims description 4
- 229940119170 jojoba wax Drugs 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000010667 rosehip oil Substances 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 claims description 3
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 3
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 3
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 3
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 claims description 3
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 3
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 claims description 3
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- -1 at least 60% Chemical compound 0.000 description 33
- 241000218236 Cannabis Species 0.000 description 29
- 229940065144 cannabinoids Drugs 0.000 description 21
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 20
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 19
- 230000006872 improvement Effects 0.000 description 19
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 description 18
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 description 18
- 239000000284 extract Substances 0.000 description 18
- 239000013543 active substance Substances 0.000 description 17
- 206010003805 Autism Diseases 0.000 description 16
- 208000020706 Autistic disease Diseases 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 12
- 230000006399 behavior Effects 0.000 description 10
- 238000006114 decarboxylation reaction Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 229930003658 monoterpene Natural products 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000000419 plant extract Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000002621 endocannabinoid Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 150000002773 monoterpene derivatives Chemical class 0.000 description 5
- 235000002577 monoterpenes Nutrition 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229940057917 medium chain triglycerides Drugs 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000003989 repetitive behavior Effects 0.000 description 4
- 208000013406 repetitive behavior Diseases 0.000 description 4
- 230000003997 social interaction Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001755 vocal effect Effects 0.000 description 4
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- 229920001688 coating polymer Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 240000004308 marijuana Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229930004725 sesquiterpene Natural products 0.000 description 3
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 229940116411 terpineol Drugs 0.000 description 3
- 229960003726 vasopressin Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- YLEARPUNMCCKMP-DOFZRALJSA-N N-arachidonoylglycine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC(O)=O YLEARPUNMCCKMP-DOFZRALJSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000033712 Self injurious behaviour Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 231100000871 behavioral problem Toxicity 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 244000213578 camo Species 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 244000038280 herbivores Species 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000008384 membrane barrier Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- IRMPFYJSHJGOPE-UHFFFAOYSA-N olivetol Chemical compound CCCCCC1=CC(O)=CC(O)=C1 IRMPFYJSHJGOPE-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- MKPMHJQMNACGDI-UHFFFAOYSA-N 1-methyl-4-prop-1-en-2-ylcyclohex-2-en-1-ol Chemical compound CC(=C)C1CCC(C)(O)C=C1 MKPMHJQMNACGDI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- VLXDPFLIRFYIME-GZBLMMOJSA-N Copaene Natural products C1C=C(C)[C@H]2[C@]3(C)CC[C@H](C(C)C)[C@H]2[C@@H]31 VLXDPFLIRFYIME-GZBLMMOJSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 102100033061 G-protein coupled receptor 55 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010019191 Head banging Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000871151 Homo sapiens G-protein coupled receptor 55 Proteins 0.000 description 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 description 1
- 101000829761 Homo sapiens N-arachidonyl glycine receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- PDSNLYSELAIEBU-UHFFFAOYSA-N Longifolene Chemical compound C1CCC(C)(C)C2C3CCC2C1(C)C3=C PDSNLYSELAIEBU-UHFFFAOYSA-N 0.000 description 1
- ZPUKHRHPJKNORC-UHFFFAOYSA-N Longifolene Natural products CC1(C)CCCC2(C)C3CCC1(C3)C2=C ZPUKHRHPJKNORC-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 102100023414 N-arachidonyl glycine receptor Human genes 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 208000024825 childhood disintegrative disease Diseases 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000013407 communication difficulty Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- VLXDPFLIRFYIME-BTFPBAQTSA-N copaene Chemical compound C1C=C(C)[C@H]2[C@]3(C)CC[C@@H](C(C)C)[C@H]2[C@@H]31 VLXDPFLIRFYIME-BTFPBAQTSA-N 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008909 emotion recognition Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009884 interesterification Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 201000003374 non-syndromic intellectual disability Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940098462 oral drops Drugs 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- GGHMUJBZYLPWFD-CUZKYEQNSA-N patchouli alcohol Chemical compound C1C[C@]2(C)[C@@]3(O)CC[C@H](C)[C@@H]2C[C@@H]1C3(C)C GGHMUJBZYLPWFD-CUZKYEQNSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- GGHMUJBZYLPWFD-UHFFFAOYSA-N rac-patchouli alcohol Natural products C1CC2(C)C3(O)CCC(C)C2CC1C3(C)C GGHMUJBZYLPWFD-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000013623 stereotypic movement disease Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This disclosure is directed to compositions including a cannabinoid combination, a terpene combination, and a carrier, wherein the terpene combination includes β- caryophyllene, linalool, a-pinene and/or limonene, and wherein the terpene combination comprises about 3-30% by weight of the cannabinoid combination
Description
COMPOSITIONS AND METHODS FOR TREATMENT OF AUTISM SPECTRUM
DISORDER
TECHNICAE FIELD
The present invention provides a composition comprising a cannabinoid combination and a terpene combination, and a method for treatment of autism spectrum disorder (ASD) by administration of said composition.
BACKGROUND ART
ASD is characterized by persistent challenges with social communication and social interaction, and by the presence of restricted, repetitive patterns of behavior, interests, or activities. These symptoms begin in early childhood and are expressed in almost all dimensions of the child’s development. About 50% of the children and youth having ASD demonstrate self-injurious behavior (SIB) such as head-banging and self-biting, which has been found to correlate with intellectual disability.
No specific treatments are currently available and interventions are focusing on lessening of the disruptive behaviors, training, and teaching self-help skills for a greater independence.
Recently, CBD enriched cannabis has been shown to be beneficial for children with autism (Aran et al., Cannabidiol based medical cannabis in children with autism - a retrospective feasibility study. Neurology, 2018, 90). For instance, a study conducted by the Ben-Gurion University of the Negev and the Soroka University Medical Center, both in Israel, explored the connection between the use of medical cannabis and autism behavioral improvements in children with autism under the age of 18, and found cannabis to be a well- tolerated, safe and effective option to relieve symptoms including seizures, tics, depression, restlessness, and rage attacks.
According to said study, 188 ASD patients were treated with various medical cannabis products. The treatment in majority of the patients was based on cannabis oil containing 30% cannabidiol (CBD) and 1.5% A9-tetrahydrocannabinol (A9-THC). Symptoms, patient global assessment, and side effects after six months of treatment were assessed by structured questionnaires, and the results showed that about 80% of the
participants reported some level of improvement. Specifically, 30% of patients reported a significant improvement, 53.7% reported moderate improvement, and only 15% had slight improvement or no change.
The study mentioned above further explored the benefits of using cannabis on the life quality of patients with autism. For example, while good life quality, positive mood, and aspects of independence such as the ability to dress and shower independently, were reported by 31.3%, 42%, and 26.4% of the patients, respectively, prior to treatment initiation, these rates were remarkably improved to 66.8%, 63.5%, and 42.9% or the patients, respectively, after six months of treatment. As further shown, cannabis oil-based medication was able to significantly improve sleep and concentration to 24.7% and 14%, respectively, during an active treatment compared to 3.3% and 0% before treatment.
The exact mechanism of the cannabis effects in patients with ASD is not fully elucidated. Findings from ASD animal models indicate a possible dysregulation of the endocannabinoid system signaling behaviors, that was suggested to be also present in ASD patients. ASD is characterized by an excitation and inhibition imbalance of gamma- aminobutyric acid (GABA) and glutamate transmission regulation in different brain structures (Zamberletti et al., The endocannabinoid system and autism spectrum disorders: insights from animal models. International journal of molecular sciences, 2017, 18, 1916). The endocannabinoid system is involved in modulating imbalanced GABAergic (Piomelli, The molecular logic of endocannabinoid signaling. Nature Reviews Neuroscience, 2003, 4, 873) and glutamatergic transmission (Colizzi et al., Effect of cannabis on glutamate signaling in the brain: A systematic review of human and animal evidence. Neuroscience & Biobehavioral Reviews, 2016, 64, 359-381).
Other mechanisms of action can involve the neurotransmitters oxytocin and vasopressin, acting as important modulators of social behaviors (Meyer-Lindenberg et al., Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nature Reviews Neuroscience, 2011, 12, 524). Administration of oxytocin to patients with ASD has been shown to facilitate processing of social information, improve emotional recognition, strengthen social interactions, reduce repetitive behaviors and increase eye gaze. CBD was found to enhance oxytocin and vasopressin release during
activities involving social interaction. In addition, the two main active ingredients, THC and CBD, in the cannabis plant may have different psychoactive action mechanisms.
SUMMARY OF INVENTION
It has now been found, in accordance with the present invention, that a composition comprising a combination of purified cannabidiol (CBD) and A9-tetrahydrocannabinol (THC) in a weight ratio of about 20:1, and a terpene combination comprising P- caryophyllene, linalool, a-pinene and limonene in a particular weight ratio, more specifically a composition referred to herein as “Nitzan Spectrum composition", was significantly more effective in limiting or attenuating co-morbid symptoms exhibited by children having ASD (e.g., hyperactivity, self-injury, social communication, and reaction to the flavor of the administered composition) than both a similar composition comprising a mixture of cannabis plant extracts as the CBD and THC sources, and a similar composition without said terpene combination, indicating that such a composition may be highly effective in treating children with ASD.
In one aspect, disclosed herein is a composition comprising a cannabinoid combination, a terpene combination, and a carrier, wherein said cannabinoid combination comprises of cannabidiol (CBD) or an enantiomer or diastereomer thereof in an, optionally partially or fully carboxylated at position 6’ thereof, and A9-tetrahydrocannabinol (A9-THC; THC) or an enantiomer or diastereomer thereof, optionally partially or fully carboxylated at position 2 thereof (see structures below); and wherein said terpene combination consists of at least three terpenes selected from P-caryophyllene, linalool, a-pinene and limonene. According to some embodiment the CBD constitutes 5-30% by weight of the composition. According to some embodiment the THC constitutes 0.08-5.0% by weight of the composition. According to some embodiment, the CBD and the THC are present in a weight ratio of 20:1. According to some embodiment, the terpene combination comprises about 0.4- 4.8% by weight of said composition. According to some embodiment, the terpene combination comprises about 3-30% or 3-20% by weight of said cannabinoid composition. Such compositions may be formulated as pharmaceutical or nutraceutical compositions, by optionally mixing with suitable one or more carriers and/or excipients.
In another aspect, the present invention relates to a method for treatment of ASD in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to any one of the embodiments above.
According to some embodiments, there is provided a composition comprising a cannabinoid combination, a terpene combination, and a carrier, wherein the cannabinoid combination comprises cannabidiol (CBD) or an enantiomer or diastereomer thereof, optionally partially or fully carboxylated at position 6’ thereof, and A9-tetrahydrocannabinol (A9-THC) or an enantiomer or diastereomer thereof, optionally partially or fully carboxylated at position 2 thereof; wherein the terpene combination comprises at least three terpenes selected from P-caryophyllene, linalool, a-pinene and limonene, and wherein the terpene combination comprises about 3-30% by weight of the cannabinoid combination.
According to some embodiments, CBD constitutes 5-30% by weight of the cannabinoid combination.
According to some embodiments, the THC constitutes 0.08-3.0% by weight of the cannabinoid combination.
According to some embodiments, the CBD and the THC are present in a weight ratio of 20:1.
According to some embodiments, terpene combination constitutes about 0.4-4.8% by weight of said composition.
According to some embodiments, the cannabinoid combination consists of CBD and A9-THC. According to some embodiments, cannabinoid combination consists of CBD in an amount of 5-27% by weight, and A9-THC in an amount of 0.1-2.5% by weight.
According to some embodiments, the terpene combination comprises a-pinene, limonene, linalool, and P-caryophyllene. According to some embodiments, the terpene combination comprises P-caryophyllene, and at least two of a-pinene, limonene, and linalool. According to some embodiments, the terpene combination consists of a-pinene, limonene, linalool, and P-caryophyllene.
According to some embodiments, the P-caryophyllene constitutes about 50-90% by weight of the terpene combination. According to some embodiments, the linalool, when present, constitutes about 10-30% by weight of the terpene combination. According to some embodiments, each one of the a-pinene and limonene, when present, independently constitutes up to 5% by weight of the terpene combination.
According to some embodiments, the terpene combination comprises P- caryophyllene in an amount of about 70% of the terpene combination, linalool in an amount of about 20% of the terpene combination, a-pinene in an amount of up to 3% of the terpene combination, and limonene in an amount of up to 3% of the terpene combination.
According to some embodiments, the carrier is beeswax, honey, or a carrier oil. According to some embodiment, the carrier oil is selected from: a medium chain triglyceride (MCT), coconut oil, canola oil, olive oil, avocado oil, grapeseed oil, hempseed oil, sunflower oil, black seed oil, rosehip oil, argan oil, palm tree oil, and jojoba oil. Each possibility is a separate embodiment. According to some embodiments, the carrier oil is an MCT.
According to some embodiments, the composition further comprises at least one additional cannabinoid such as cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), cannabidiphorol (CBDP), cannabidiol monomethyl ether (CBDM), cannabidiol-C4 (CBD- C4), cannabidiorcol (CBD-C1), A9-tetrahydrocannabivarin (A9-THCV), A9-THCVA, A8- THC, A8-THCA, A8-THCV, A8-THCVA, A9-tetrahydrocannabiphorol (A9-THCP), iso- tetrahydrocannabinol-type (iso-THC), cannabinol (CBN), cannabinolic acid (CBNA), cannabinol-C4 (CBN-C4), cannabinol-C2 (CBN-C2), cannabiorcol (CBN-C1), cannabinol methyl ether (CBNM), cannabinodiol (CBND), cannabigerol (CBG), cannabigero varin (CBGV), cannabigerolic acid (CBGA), cannabigerovarinic acid (CBGVA), cannabigerol monomethyl ether (CBGM), cannabigerolic acid monomethyl ether (CBGAM), cannabichromene (CBC), cannabichromenic acid (CBCA), cannabichromevarin (CBCV),
cannabichromevarinic acid (CBCVA), cannabichromanon (CBCN), cannabicyclol (CBL), cannabicyclolic acid (CBLA), cannabicyclovarin (CBLV), cannabivarin (CBV), cannabivarinic acid (CBVA), cannabielsoin (CBE), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabitriol (CBT), cannabitriolvarin (CBTV), ethoxy- cannabitiolvarin (CBTVE), cannabifuran (CBF), dehydrocannabifuran (DCBF), cannabiripsol (CBR), or an enantiomer, diastereomer, racemate, or a salt thereof. Each possibility is a separate embodiment.
According to some embodiments, the at least one additional cannabinoid constitutes up to 5% by weight of the composition.
According to some embodiments, the composition is formulated as an emulsion, e.g., an oil-in edible solvent emulsion.
According to some embodiments, at least one of the CBD, the THC, the P- caryophyllene, the linalool, the a-pinene or the limonene is in a form of synthetic, purified, extracted or isolated molecules.
According to some embodiments, the composition is a pharmaceutical or a nutraceutical composition. According to some embodiments, the pharmaceutical composition is formulated for oral, buccal or sublingual administration, or for inhalation (e.g., vaporization). According to some embodiments, the pharmaceutical composition is formulated as a liquid dosage form, such as a solution, syrup and elixir; or as a solid dosage form such as a tablet, capsule, and pill. Each possibility is a separate embodiment. According to some embodiments, the nutraceutical composition is formulated as a food supplement, drink or beverage.
According to some embodiments, the composition is for use in the treatment of autism spectrum disorder (ASD).
According to some embodiments, the composition is suitable for use for reducing hyperactivity symptoms, reducing self-injury behavior, improving sleeping, and/or improving social communication in a suffering from autism spectrum disorder (ASD).
According to some embodiments, there is provided a method for treatment of autism spectrum disorder (ASD) in a subject in need thereof, the method comprising
administering to said subject a therapeutically effective amount of the herein disclosed composition.
Certain embodiments of the present disclosure may include some, all, or none of the above advantages. One or more technical advantages may be readily apparent to those skilled in the art from the figures, descriptions and claims included herein. Moreover, while specific advantages have been enumerated above, various embodiments may include all, some or none of the enumerated advantages.
In addition to the exemplary aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the figures and by study of the following detailed descriptions.
BRIEF DESCRIPTION OF DRAWINGS
Fig. 1 shows the hyperactivity symptoms (e.g., how much calm the kid was, the rate of hyper events and duration thereof, and how easy was it to get the kid out of the event) in the participating kids. The Y axis shows the satisfaction level (scored by parents from 0- 10; 10 being the highest positive score) and the X axis refers to the duration of testing (in weeks).
Fig. 2 shows the symptom of self-injury (e.g., self-harming, knocking the head in the wall, scratching the arms). The Y axis shows the satisfaction level (scored by parents from 0-10; 10 being the highest positive score) and the X axis refers to the duration of testing (in weeks).
Fig. 3 shows how much the sleeping problems (e.g., getting to sleep, waking at night, and disturbed sleeping) were improved during the trial time. The Y axis shows the satisfaction level (scored by parents from 0-10; 10 being the highest positive score) and the X axis refers to the duration of testing (in weeks).
Fig. 4 shows the improvement in social communications (e.g., making eye contact with the caretaker, reaction to physical contact, pronouncing the needs in words or gestures)
during the trial time. The Y axis shows the satisfaction level (scored by parents from 0-10;
10 being the highest positive score) and the X axis refers to the duration of testing (in weeks).
Fig. 5 shows the reaction to the taste of the medicine. The graph shows the improvement, according to the parents, in taking the medicine during the trial time. The Y axis shows the satisfaction level (scored by parents from 0-10; 10 being the highest positive score) and the X axis refers to the duration of testing (in weeks).
Fig. 6 shows the average of all the criterions tested in Figs. 1-5 (hyperactivity symptoms, self-injury, sleeping problems, social communication, and flavor improvement) according to a parent’s report.
Fig. 7 shows ADOS social affect (SA), restricted and repetitive behaviors (RRB), total raw score, and calibrated severity score (CSS).
Fig. 8 shows Vineland total score and Socialization, Daily living and Communication subscale scores.
Fig. 9 shows efficacy data validated ASD questionnaires and analyzed in order to demonstrate the efficacy of Nitzan Spectrum in ASD population.
DETAILED DESCRIPTION
In one aspect, the present invention provides a composition comprising a cannabinoid combination, a terpene combination, and a carrier, wherein said cannabinoid combination consists of CBD or an enantiomer or diastereomer thereof, optionally partially or fully carboxylated at position 6’ thereof, and THC or an enantiomer or diastereomer thereof, optionally partially or fully carboxylated at position 2 thereof; and wherein said terpene combination consists of at least three terpenes selected from P-caryophyllene, linalool, a-pinene and limonene. According to some embodiments, the CBD and the THC are present in a weight ratio of 20: 1. According to some embodiment the CBD constitutes 5- 30% by weight of the composition. According to some embodiment the THC constitutes 0.08-5.0% by weight of the composition. According to some embodiment the terpene combination comprises constitutes about 0.4-4.8% by weight of said composition.
According to some embodiment, the terpene combination comprises about 3-30%, 3-20%, 3-15%, 5-20% or 7-15% by weight of said cannabinoid composition. Each possibility is a separate embodiment.
The term “cannabinoid” as used herein refers to a chemical compound acting on cannabinoid receptors, i.e., a cannabinoid type 1 (CB1) and/or cannabinoid type 2 (CB2) receptor and/or the G protein-coupled receptor GPR55 and/or the N-arachidonoyl glycine (NAGly) receptor GPR18 and/or GPR119 and/or the PP AR family of nuclear hormone receptors . Ligands for these receptor proteins include the endocannabinoids produced naturally in the body; the phytocannabinoids found in Cannabis saliva. Cannabis indica, Cannabis ruderalis. and some other plants; and synthetic cannabinoids.
According to some embodiments, at least one of the CBD, the THC, the P- caryophyllene, the linalool, the a-pinene or the limonene is in a form of synthetic, extracted, isolated, or purified molecule.
As used herein, the term “synthetic” refers to a chemically synthesized molecule. As used herein, the term “extracted” refer to a molecule extracted from a natural source and added to the mixture. As a non-limiting example, an extracted terpene may also include additional components (e.g., additional terpenes), which are added to the composition, but which are not part of the plant/extract from which the cannabinoid combination. As used herein, the term “isolated” refers to a molecule which is extracted from a natural resource, so as to become the major component, but may also include smaller amounts of other component. As a non-limiting example, isolated linalool refers to an extract containing mostly linalool, e.g., at least 60%, at least 70% at least 80% or at least 90% linalool or at least 98% linalool. Each possibility is a separate embodiment. As used herein, the term “purified” refers to a molecule which is isolated from a natural resource, and purified so as to become the essentially only component, i.e., other component are present in residual amounts only. As a non-limiting example, purified a-pinene refers to an extract containing essentially only a-pinene, e.g., less than 90% or less than 95% or less than 98% of other components. Each possibility is a separate embodiment.
The composition disclosed herein comprises a cannabinoid combination and a terpene combination, also referred to herein together as “the active agent combination
According to the invention, each one of the active agents comprised within the composition, i.e., each one of the cannabinoids and each one of the terpenes, can independently be either naturally produced and optionally purified, or synthetic. For the sake of simplicity, and if not otherwise explicitly specified, all references made throughout this specification to CBD refer to an enantiomer or diastereomer thereof as well, and all references made to THC also refer to an enantiomer or diastereomer thereof.
The composition disclosed herein comprises a cannabinoid combination consisting of CBD and THC, wherein the amount of each one of said cannabinoids is within the particular range disclosed, and the ratio between said CBD and THC thus ranges, e.g., between 100:1 to 6:1, 80:1 to 8:1, 60:1 to 10:1, 40:1 to 15:1, or 25:1 to 16:1, respectively. In particular embodiments, the amounts of said cannabinoids are determined such that the ratio between the CBD and THC ranges from about 24:1 to 18:1, e.g., about 22:1, 21:1, 20:1, 19:1, or 18:1, respectively.
Yet, it should be understood that some and even all of either or both the CBD and THC may exist as the carboxylated form thereof, i.e., as cannabidiolic acid (CBDA), or an enantiomer or diastereomer thereof; or A9-tetrahydrocannabinolic acid (A9-THCA), or an enantiomer or diastereomer thereof, A8-tetrahydrocannabinolic acid (A8-THCA), or an enantiomer or diastereomer thereof respectively (for the sake of simplicity, all references made herein to CBDA refer to an enantiomer or diastereomer thereof as well, and all references made to THC A also refer to an enantiomer or diastereomer thereof). In other words, the CBD comprised within the composition of the present invention may be partially or fully replaced with an equivalent molar amount of CBDA, and/or the THC comprised within said composition may be partially or fully replaced with an equivalent molar amount of THCA.
The terms “partially carboxylated” and “fully carboxylated” as used herein with respect to one or both of the cannabinoids comprised within the composition of the invention means that either a partial or full amount of said cannabinoid is carboxylated, i.e., present in the acidic form thereof. The term “equivalent molar amount” as used herein means that the amount of each one of CBDA and/or THCA, when present in the composition, is equivalent in moles to the amount of CBD and/or THC replaced by said CBDA and/or THCA, respectively. According to some embodiments the overall amount of CBD in the
composition, i.e., the amount of CBD present plus the amount of CBD obtainable by decarboxylation of said CBDA, when present, is 2-30%, 5-20% or 6-15% by weight. Each possibility is a separate embodiment. According to some embodiments, the overall amount of THC in the composition, i.e., the amount of THC present plus the amount of THC obtainable by decarboxylation of said THCA, when present, is 0.08-3.0%, 0.1-2% or 0.3- 1% by weight. Each possibility is a separate embodiment.
In certain embodiments, the cannabinoid combination comprised within the composition of the invention consists of CBD and THC.
In other embodiments, the CBD is partially replaced by the carboxylated form thereof, i.e., said cannabinoid combination consists of CBD; CBDA; and THC. According to some embodiments, the amount of CBD present and the amount of CBD obtainable by decarboxylation of said CBDA sum up to 2-30%, 5-20% or 6-15% by weight. Each possibility is a separate embodiment.
In further embodiments, the CBD is fully replaced by the carboxylated form thereof, i.e., said cannabinoid combination consists of CBDA; and THC, wherein the amount of CBD obtainable by decarboxylation of said CBDA is 2-30%, 5-20% or 6-15% by weight. Each possibility is a separate embodiment.
In still other embodiments, the THC is partially replaced by the carboxylated form thereof, i.e., said cannabinoid combination consists of CBD; THC; and THCA, wherein the amount of THC present and the amount of THC obtainable by decarboxylation of said THCA sum up to 0.08-3.0%, 0.1-2% or 0.3-1% by weight.
In still further embodiments, the THC is fully replaced by the carboxylated form thereof, i.e., said cannabinoid combination consists of CBD; and THCA, wherein the amount of THC obtainable by decarboxylation of said THCA is 0.08-3.0%, 0.1-2% or 0.3-1% by weight. Each possibility is a separate embodiment.
In yet other embodiments, each one of the CBD and the THC is partially replaced by the carboxylated form thereof, i.e., said cannabinoid combination consists of CBD; CBDA; THC; and THCA, wherein the amount of CBD present and the amount of CBD obtainable by decarboxylation of said CBDA sum up to 12-30% by weight; and the amount
of THC present and the amount of THC obtainable by decarboxylation of said THCA sum up to 0.08-3.0%, 0.1-2% or 0.3-1% by weight. Each possibility is a separate embodiment.
In yet further embodiments, each one of the CBD and the THC is fully replaced by the carboxylated form thereof, i.e., said cannabinoid combination comprised within the composition of invention consists of CBDA; and THCA, wherein the amount of CBD obtainable by decarboxylation of said CBDA sum up to 2-30%, 5-20% or 6-15% by weight; and the amount of THC obtainable by decarboxylation of said THCA sum up to 0.08-3.0%, 0.1-2% or 0.3-1% by weight. Each possibility is a separate embodiment.
In certain embodiments, the cannabinoid combination comprised within the composition of the present invention consists of CBD, i.e., 2-[(17?,67?)-6-isopropenyl-3- methylcyclohex-2-en-l-yl]-5-pentylbenzene-l,3-diol, optionally partially or fully carboxylated at position 6’ thereof; and THC, i.e., (6a7?,10a7?)-6,6,9-trimethyl-3-pentyl- 6a,7,8,10a-tetrahydro-6//-benzo[c]chromen-l-ol, optionally partially or fully carboxylated at position 2 thereof. In particular such embodiments, said cannabinoid combination consists of (i) CBD and THC only; (ii) a mixture of CBD and CBDA, and THC; (iii) CBD, and a mixture of THC and THCA; or (iv) a mixture of CBD and CBDA, and a mixture of THC and THCA, wherein the molar ratio between the CBD and CBDA, when both present, and the molar ratio between the THC and THCA, when both present, each independently is in a range of, e.g., about 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 18:1, 16:1, 14:1, 12:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:12, 1:14, 1:16, 1:18, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, or 1:100, respectively. In more particular such compositions, the overall amount of CBD is about 2-30%, 5-15% 12-30%, e.g., about 15-27%, about 17-23%, or about 20%, by weight, and the overall amount of THC is about 0.08-3%, about 0.1-2.5%, about 0.5-2%, or about 1-1.5%, by weight.
The term “terpene” as used herein refers to a hydrocarbon produced by a variety of plants and by some insects. Terpenes often have a strong odor, and may protect the plants producing them by deterring herbivores and by attracting predators and parasites of herbivores. Terpenes are also major biosynthetic building blocks. Steroids, for example, are derivatives of the triterpene squalene. The term “terpenoid” (also referred to as isoprenoid) as used herein refers to a modified terpene containing a functional group, usually an oxygencontaining group. As stated above, the terpenes comprised within the composition of the
invention may independently be either naturally produced and optionally purified, or synthetic.
Terpenes and terpenoids are the primary constituents of the essential oils of many types of plants and flowers. Essential oils are used widely as fragrances in perfumery and traditional medicine, such as aromatherapy. Synthetic variations and derivatives of natural terpenes and terpenoids also greatly expand the variety of aromas used in perfumery and flavors used in food additives.
Monoterpenes are a class of terpenes consisting of two isoprene units and having the molecular formula C10H16. Monoterpenes may be linear (acyclic) or contain rings (cyclic). Modified terpenes, such as those containing oxygen functionality or missing a methyl group, are called monoterpenoids. Monoterpenes and monoterpenoids are used in the pharmaceutical, cosmetic, agricultural, and food industries.
Sesquiterpenes are a class of terpenes consisting of three isoprene units and often have the molecular formula C15H24. Like monoterpenes, sesquiterpenes may be acyclic or contain rings, including many unique combinations. Biochemical modifications such as oxidation or rearrangement produce the related sesquiterpenoids.
Non-limiting examples of monoterpenes or monoterpenoids comprised within the terpene combination of the invention include a pinene selected from a-pinene, P-pinene, and y-pinene, limonene, linalool, myrcene, camphene, nerol, geraniol, a terpineol selected from a-terpineol, P-terpineol, y-terpineol, and terpinen-4-ol, or an enantiomer or diastereomer thereof; and non-limiting examples of sesquiterpene or sesquiterpenoid comprised within the terpene combination of the invention include longifolene, copaene, patchoulol, farnesol, humulene, famesene, P-caryophyllene, or an enantiomer or diastereomer thereof.
In certain embodiments, the terpene combination comprised within the composition of the invention consists of at least three of a-pinene or an enantiomer thereof, limonene or an enantiomer thereof, linalool or an enantiomer thereof, and P-caryophyllene or an enantiomer or diastereomer thereof, e.g., a-pinene, limonene, and linalool; a-pinene, limonene, and P-caryophyllene; a-pinene, linalool, and P-caryophyllene; limonene, linalool, and P-caryophyllene; or a-pinene, limonene, linalool, and P-caryophyllene.
In particular such embodiments, the terpene combination comprised within the composition of the invention consists of P -caryophyllene, and at least two of a-pinene, limonene, and linalool. In particular such embodiments, the P -caryophyllene constitutes about 50-90%, e.g., about 60-80%, or about 70%, by weight of said terpene combination; the linalool, when present, constitutes about 10-30%, e.g., about 15-25%, or about 20%, by weight of said terpene combination; and each one of the a-pinene and limonene, when present, independently constitutes up to 5%, e.g., about 0.1-4%, 0.5-3.5%, or less than 3%, by weight of said terpene combination. More partiuclar such terpene combinations are those consisting of P-caryophyllene, linalool, and a-pinene; P-caryophyllene, linalool, and limonene; P-caryophyllene, a-pinene, and limonene; or P-caryophyllene, linalool, a-pinene, and limonene. Specific such terpene combinations consist of P-caryophyllene in an amount of about 70% of said terpene combination, linalool in an amount of about 20% of said terpene combination, a-pinene in an amount of up to 3% of said terpene combination, and limonene in an amount of up to 3% of said terpene combination.
The composition disclosed herein comprises, in addition to said cannabinoid and terpene combinations, a carrier. In certain embodiments, said carrier is beeswax or honey. In other embodiments, the carrier is a carrier oil, i.e., a vegetable oil (also known as base oil) derived from the fatty portion (usually from the seeds, kernels, or nuts) of a plant. Nonlimiting examples of carrier oils include a medium chain triglyceride (MCT), coconut oil, canola oil, olive oil, avocado oil, grapeseed oil, hempseed oil, sunflower oil, black seed oil, rosehip oil, argan oil, palm tree oil, and jojoba oil. In particular such embodiments, the carrier oil comprised within the composition of the invention is an MCT. According to some embodiments, the carrier oil comprises olive oil. According to some embodiments, the carrier oil comprises an MCT alone or in combination with an oil, such as but not limited to olive oil.
Medium chain triglycerides (MCTs) are triglycerides with two or three medium chain fatty acids, i.e., fatty acids having an aliphatic tail of 6-12 carbon atoms such as hexanoic acid, octanoic acid, decanoid acid, and dodecanoic acid. MCTs are found in palm kernel oil and coconut oil, and may be separated by fractionation. Alternatively, they may be produced by, e.g., interesterification, i.e., a process that rearranges the fatty acids of a fat product.
In certain embodiments, the composition disclosed herein comprises a cannabinoid combination comprising CBD, i.e., 2-[(17?,67?)-6-isopropenyl-3-methylcyclohex-2-en-l-yl]- 5 -pentylbenzene- 1,3 -diol, optionally partially or fully carboxylated at position 6’ thereof, and THC, i.e., (6a7?,10a/?)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6/Z- benzo[c]chromen-l-ol, optionally partially or fully carboxylated at position 2 thereof, according to any one of the embodiments above; a terpene combination consisting of at least three of a-pinene, limonene, linalool, and P-caryophyllene; and MCT as a carrier oil. Particular such compositions comprise a trerpene combination consisting of a-pinene, limonene, and linalool; a-pinene, limonene, and P-caryophyllene; a-pinene, linalool, and P- caryophyllene; limonene, linalool, and P-caryophyllene; or a-pinene, limonene, linalool, and P-caryophyllene.
In particular such embodiments, said cannabinoid combination comprising CBD optionally partially or fully carboxylated at position 6’ thereof, in an amount of about 2- 30%, 5-15%, 15-27%, about 17-23%, or about 20%, by weight, and THC optionally partially or fully carboxylated at position 2 thereof, in an amount of about 0.1-2.5%, about 0.5-2%, or about 1-1.5%, by weight; and said terpene combination consists of P-caryophyllene, and at least two of a-pinene, limonene, and linalool, wherein the P-caryophyllene constitutes about 50-90% by weight of said terpene combination; the linalool, when present, constitutes about 10-30% by weight of said terpene combination; and each one of the a-pinene and limonene, when present, independently constitutes up to 5% by weight of said terpene combination. More particular such embodiments are those wherein said terpene combination consists of P-caryophyllene in an amount of about 70% of said terpene combination, linalool in an amount of about 20% of said terpene combination, and a-pinene and limonene, each in an amount of up to 3% of said terpene combination.
In certain embodiments, the composition of the invention, according to any one of the embodiments above, further comprises at least one additional cannabinoid, i.e., one, two, three, four, or more cannabinoids in addition to the CBD (and/or CBDA) and THC (and/or THCA) present. Examples of such cannabinoids include, without being limited to, cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), cannabidiphorol (CBDP), cannabidiol monomethyl ether (CBDM), cannabidiol-C4 (CBD-C4), cannabidiorcol (CBD- Cl), A9-tetrahydrocannabivarin (A9-THCV), A9-THCVA, A8-THC, A8-THCA, A8-THCV,
A8-THCVA, cannabidiphorol (CBDP), iso-tetrahydrocannabinol-type (iso-THC), cannabinol (CBN), cannabinolic acid (CBNA), cannabinol-C4 (CBN-C4), cannabinol-C2 (CBN-C2), cannabiorcol (CBN-C1), cannabinol methyl ether (CBNM), cannabinodiol (CBND), cannabigerol (CBG), cannabigerovarin (CBGV), cannabigerolic acid (CBGA), cannabigerovarinic acid (CBGVA), cannabigerol monomethyl ether (CBGM), cannabigerolic acid monomethyl ether (CBGAM), cannabichromene (CBC), cannabichromenic acid (CBCA), cannabichromevarin (CBCV), cannabichromevarinic acid (CBCVA), cannabichromanon (CBCN), cannabicyclol (CBL), cannabicyclolic acid (CBLA), cannabicyclovarin (CBLV), cannabivarin (CBV), cannabivarinic acid (CBVA), cannabielsoin (CBE), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabitriol (CBT), cannabitriolvarin (CBTV), ethoxy-cannabitiolvarin (CBTVE), cannabifuran (CBF), dehydrocannabifuran (DCBF), cannabiripsol (CBR), or an enantiomer, diastereomer, racemate, or a salt thereof. In particular such embodiments, said at least one additional cannabinoid constitutes up to 2.5% by weight of said composition, i.e., the overall amount of said additional cannabinoids sum up to not more than 5% by weight of said composition.
Each one of the cannabinoids comprised within the composition of the present invention, i.e., either or both of the CBD (when fully or partially present as CBDA) and THC (when fully or partially present as THCA), as well as any one of the additional cannabinoids when present, may be present in a salt, e.g., a pharmaceutically acceptable salt, form.
Suitable pharmaceutically acceptable salts include salts of ammonium (NH4+) or an organic cation derived from an amine of the formula R4N+, wherein each one of the Rs independently is selected from H, C1-C22, preferably Ci-Ce alkyl, such as methyl, ethyl, propyl, isopropyl, n-butyl, sec -butyl, isobutyl, tert-butyl, n-pentyl, 2,2-dimethylpropyl, n- hexyl, and the like, phenyl, or heteroaryl such as pyridyl, imidazolyl, pyrimidinyl, and the like, or two of the Rs together with the nitrogen atom to which they are attached form a 3-7 membered ring optionally containing a further heteroatom selected from N, S and O, such as pyrrolydine, piperidine and morpholine. Additional suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g., lithium, sodium or potassium salts, and alkaline earth metal salts, e.g., calcium or magnesium salts.
Further pharmaceutically acceptable salts include salts of a cationic lipid or a mixture of cationic lipids. Cationic lipids are often mixed with neutral lipids prior to use as delivery agents. Neutral lipids include, but are not limited to, lecithins; phosphatidylethanolamine; diacyl phosphatidylethanolamines such as dioleoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, palmitoyloleoyl phosphatidylethanolamine and distearoyl phosphatidylethanolamine; phosphatidylcholine; diacyl phosphatidylcholines such as dioleoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, palmitoyloleoyl phosphatidylcholine and distearoyl phosphatidylcholine; phosphatidylglycerol; diacyl phosphatidylglycerols such as dioleoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol and distearoyl phosphatidylglycerol; phosphatidylserine; diacyl phosphatidylserines such as dioleoyl- or dipalmitoyl phosphatidylserine; and diphosphatidylglycerols; fatty acid esters; glycerol esters; sphingolipids; cardiolipin; cerebrosides; ceramides; and mixtures thereof. Neutral lipids also include cholesterol and other 3P hydroxy-sterols.
Examples of cationic lipid compounds include, without being limited to, Lipofectin® (Life Technologies, Burlington, Ontario) (1:1 (w/w) formulation of the cationic lipid N-[l-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride and dioleoylphosphatidyl-ethanolamine); Lipofectamine™ (Life Technologies, Burlington, Ontario) (3:1 (w/w) formulation of polycationic lipid 2,3-dioleyloxy-N-[2(spermine- carboxamido)ethyl]-N,N-dimethyl-l-propanamin-iumtrifluoroacetate and dioleoylphosphatidyl-ethanolamine), Lipofectamine Plus (Life Technologies, Burlington, Ontario) (Lipofectamine and Plus reagent), Lipofectamine 2000 (Life Technologies, Burlington, Ontario) (Cationic lipid), Effectene (Qiagen, Mississauga, Ontario) (Non liposomal lipid formulation), Metafectene (Biontex, Munich, Germany) (Polycationic lipid), Eu-fectins (Promega Biosciences, San Luis Obispo, Calif.) (ethanolic cationic lipids numbers 1 through 12: C52H106N6O44CF3CO2H, C88Hi78N8O4S2-4CF3CO2H,
C40H84NO3PCF3CO2H, C50H103N7O3-4CF3CO2H, C55HII6N8O2-6CF3CO2H, C49H102N6O34CF3CO2H, C44H89N5O3-2CF3CO2H, C100H206N12O4S28CF3CO2H,
C 162H330N22O9- 13CF3CO2H, C43H88N4O2-2CF3CO2H, C43H88N4O3-2CF3CO2H,
C4iH78NO8P); Cytofectene (Bio-Rad, Hercules, Calif.) (mixture of a cationic lipid and a neutral lipid), GenePORTER® (Gene Therapy Systems, San Diego, Calif.) (formulation of
a neutral lipid (Dope) and a cationic lipid) and FuGENE 6 (Roche Molecular Biochemicals, Indianapolis, Ind.) (Multi-component lipid based non-liposomal reagent).
Pharmaceutically acceptable salts of cannabinoids for use in the composition disclosed herein may be formed by conventional means, e.g., by reacting a free carboxylic acid-containing cannabinoid with one or more equivalents of an appropriate base in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze drying, or by exchanging the cation of an existing salt for another cation on a suitable ion exchange resin.
In certain embodiments, the composition disclosed herein, according to any one of the embodiments above, consists essentially of a carrier as defined above, e.g., beeswax, honey, or a carrier oil such as MCT; and a cannabis plant extract, e.g., an extract obtained from the species Cannabis sativa, Cannabis indica, or Cannabis ruderalis, or from a hybrid cannabis strain, i.e., a mix (hybrid) of two classes of cannabis such as Cannabis sativa, Cannabis indica, a fraction thereof, or a combination thereof. Such extracts may be obtained by any method or technique known in the art, and from any part of the plant but preferably from the flowering. Particular such compositions exemplified herein essentially consist of mixtures of extracts obtained from Cannabis TIL Tachllta (Israel Plant Breeders' Rights Application No. 4837/19, filed 16.07.2019) and Cannabis ZIV Sparkling Light (Israel Plant Breeders' Rights Application No. 4852/19, filed 21.08.2019) (Israel Plant Breeders' Rights Gazette No. 94, July 1, 2019-December 31, 2019).
In other embodiments, the composition of the present invention, according to any one of the embodiments above, comprises a cannabinoid combination, a terpene combination, and optionally further one or more cannabinoids, wherein each one of the cannabinoids and terpenes composing said composition, or at least the majority thereof, is either synthetic or purified.
The term “consisting/consist essentially of’ as used herein with respect to the disclosed composition means that all the components of said composition except for the carrier oil, i.e., the CBD (and/or CBDA) and THC (and/or THCA) constituting the cannabinoid combination, the terpenes constituting the terpene combination, as well as one or more of the additional cannabinoids optionally present, or at least the majority of said
components, each in the required weight percent thereof, are derived from a cannabis plant extract, a fraction thereof, or a combination thereof. Yet, it should be clear that compositions which are based on a cannabis plant extract (or fraction or combination thereof) may be enriched with purified and/or synthetic components so as to, e.g., increase the weight percentage of one or more of the cannabinoids and/or terpenes present in said extract (or fraction or combination thereof), or add one or more cannabinoid and/or terpene not present in said extract (or fraction or combination thereof).
In certain embodiments, the composition disclosed herein, according to any one of the embodiments above, is formulated as an emulsion, more particularly an oil-in-edible solvent emulsion. The term “edible solvent” as used herein means a solvent that is safe for human consumption, i.e., edible by human. Edible solvents may be polar or non-polar, and include water, as well as any edible organic solvent such as alcohols including ethanol (ethyl alcohol), propylene glycol (propane- 1,2-diol), 1,3 -butylene glycol, and glycerol (glycerine), diethyl ether (ether), vinegar (an aqueous solution of actic acid), and the like.
Particular such compositions may comprise a carrier oil as defined above, e.g., an MCT, coconut oil, canola oil, olive oil, avocado oil, grapeseed oil, hempseed oil, sunflower oil, black seed oil, rosehip oil, argan oil, palm tree oil, or jojoba oil, and be formulated as, e.g., an oil-in-water or oil-in-alcohol emulsions. Other compositions may be based on the the active agent combination, emulsified in either water or an edible alcohol using a surfactant (surface active substance), i.e., a compound that lowers the surface tension of a liquid, the interfacial tension between two liquids, or that between a liquid and a solid; and/or an emulsifier (also referred to as "emulgent"), i.e., a substance that stabilizes an emulsion by increasing its kinetic stability, e.g., a "surface active substance". Non-limiting examples of suitable surfactants include polysorbate surfactants such as Tween-80, Tween-60, Tween- 40, Tween-20, Tween-65 and Tween-85, and sorbitane surfactants such as Span 20, Span 40, Span 60, Span 80 and Span 85. Particular such compositions, when formulated as an emulsion, comprises Tween-80 as a surface active substance.
Each one of the cannabinoids and terpenes comprised within the composition of the present invention may be derived from a cannabis extract, using any suitable extraction and purification procedures known in the art, or alternatively may be synthesized following any one of the procedures disclosed in the literature. For instance, CBD may be synthesized
following any one of the procedures known in the art, e.g., by acid condensation of p- mentha-2,8-dien-l-ol with olivetol. Optically active forms of CBD may be prepared using any one of the methods disclosed in the art, e.g., by resolution of the racemic form by recrystallization techniques; chiral synthesis; extraction with chiral solvents; or chromatographic separation using a chiral stationary phase. A non-limiting example of a method for obtaining optically active materials is transport across chiral membranes, i.e., a technique whereby a racemate is placed in contact with a thin membrane barrier, the concentration or pressure differential causes preferential transport across the membrane barrier, and separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through. Chiral chromatography, including simulated moving bed chromatography, can also be used. A wide variety of chiral stationary phases are commercially available.
The compositions disclosed herein may be formulated as pharmaceutical compositions or nutraceutical compositions, optionally mixed with one or more suitable carriers and/or excipients.
In one particular such aspect, the composition of the present invention as defined in any one of the embodiments above is in a form of a pharmaceutical composition, i.e., the carrier comprised within said composition is a pharmaceutically acceptable carrier or pharmaceutically acceptable excipient.
The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" as used herein interchangeably refers to any and all solvents, dispersion media, preservatives, antioxidants, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. According to the present invention, the pharmaceutically acceptable carrier may further comprise ingredients aimed at enhancing the activity of the active agents, i.e., the cannabinoid combination and/or the terpene combination, or modulating the bioavailability thereof.
The term "acceptable" with respect to the pharmaceutically acceptable carrier denotes a carrier, excipient, or non-active ingredient that does not produce an adverse, allergic, or other untoward reaction when administered to a mammal or human as appropriate. For human administration, compositions should meet sterility, pyrogenicity,
and general safety and purity standards as required by, e.g., the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Therapeutic Goods Administration (Australia), the Medicines and Healthcare products Regulatory Agency (United Kigdom), or the Pharmaceuticals and Medical Devices Agency (Japan).
The pharmaceutical composition disclosed herein may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19th Ed., 1995. The compositions can be prepared, e.g., by uniformly and intimately bringing the active agents into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulation. The compositions may be formulated as a liquid dosage form, e.g., solution, emulsion, suspension, syrup, or elixir; or as a solid dosage form, e.g., a tablet, capsule, and pill, and may further include pharmaceutically acceptable fillers, carriers, diluents or adjuvants, and other inert ingredients and excipients. Preferred are compositions formulated as liquid dosage forms.
The pharmaceutical composition of the present invention may be formulated for any suitable route of administration, e.g., for oral, buccal, sublingual, or parenteral, e.g., intravenous, intraarterial, intramuscular, intraperitoneal, intrathecal, intrapleural, intratracheal, subcutaneous, or topical, administration, as well as for inhalation, e.g., cold or hot vaporization, but is preferably formulated for oral or sublingual administration, or for inhalation.
The pharmaceutical compositions of the invention, when formulated for oral administration, may be in any suitable form, e.g., tablets, troches, lozenges, aqueous, or oily suspensions, dispersible powders or granules, emulsions, solutions, hard or soft capsules, or syrups or elixirs. In certain embodiments, said tablets are in the form of matrix tablets in which the release of a soluble active is controlled by having the active diffuse through a gel formed after the swelling of a hydrophilic polymer brought into contact with dissolving liquid (in vitro) or gastro-intestinal fluid (in vivo). Many polymers have been described as capable of forming such gel, e.g., derivatives of cellulose, in particular the cellulose ethers such as hydroxypropyl cellulose, hydroxymethyl cellulose, methylcellulose or methyl hydroxypropyl cellulose, and among the different commercial grades of these ethers are those showing fairly high viscosity. In other embodiments, the tablets are formulated as bi- or multi-layer tablets, made up of two or more distinct layers of granulation compressed
together with the individual layers lying one on top of another, with each separate layer containing a different active agent. Bilayer tablets have the appearance of a sandwich since the edge of each layer or zone is exposed.
Pharmaceutical compositions for oral administration might be formulated so as to inhibit the release of one or both of the active agents, i.e., the cannabinoid combination and/or the terpene combination, in the stomach, i.e., delay the release of one or both of the active agents until at least a portion of the dosage form has traversed the stomach, in order to avoid the acidity of the gastric contents from hydrolyzing the active agent. Particular such compositions are those wherein the active agent is coated by a pH-dependent enteric-coating polymer. Examples of pH-dependent enteric-coating polymer include, without being limited to, Eudragit® S (poly(methacrylicacid, methylmethacrylate), 1:2), Eudragit® L 55 (poly (methacrylicacid, ethylacrylate), 1:1), Kollicoat® (poly(methacrylicacid, ethylacrylate), 1:1), hydroxypropyl methylcellulose phthalate (HPMCP), alginates, carboxymethylcellulose, and combinations thereof. The pH-dependent enteric-coating polymer may be present in the composition in an amount from about 10% to about 95% by weight of the entire composition.
In certain embodiments, the invention provides a pharmaceutical composition for oral administration, which is solid and may be in the form of granulate, granules, grains, beads or pellets, mixed and filled into capsules or sachets, or compressed to tablets by conventional methods. In some particular embodiments, the pharmaceutical composition is in the form of a bi- or multilayer tablet, in which each one of the layers comprise one of the two active agents, and the layers are optionally separated by an intermediate, inactive layer, e.g., a layer comprising one or more disintegrants.
Another contemplated formulation is depot systems, based on biodegradable polymers. As the polymer degrades, the active agent(s) is slowly released. The most common class of biodegradable polymers is the hydrolytically labile polyesters prepared from lactic acid, glycolic acid, or combinations of these two molecules. Polymers prepared from these individual monomers include poly (D,L-lactide) (PLA), poly (glycolide) (PGA), and the copolymer poly (D,L-lactide-co-glycolide) (PLG).
Pharmaceutical compositions for oral administration may be prepared according to any method known to the art and may further comprise one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active agents in admixture with non-toxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets. These excipients may be, e.g., inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, e.g., corn starch or alginic acid; binding agents, e.g., starch, gelatin or acacia; and lubricating agents, e.g., magnesium stearate, stearic acid, or talc. The tablets may be either uncoated or coated utilizing known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated using the techniques described in the US Patent Nos. 4,256,108, 4,166,452 and 4,265,874 to form osmotic therapeutic tablets for control release. The pharmaceutical composition of the invention may also be in the form of oil-in-water emulsion.
Useful dosage forms of the pharmaceutical compositions include orally disintegrating systems including, but not limited to, solid, semi-solid and liquid systems including disintegrating or dissolving tablets, soft or hard capsules, gels, fast dispersing dosage forms, controlled dispersing dosage forms, caplets, films, wafers, ovules, granules, buccal/mucoadhesive patches, powders, freeze dried (lyophilized) wafers, chewable tablets which disintegrate with saliva in the buccal/mouth cavity and combinations thereof. Useful films include, but are not limited to, single layer stand-alone films and dry multiple layer stand-alone films.
The pharmaceutical composition of the invention may comprise one or more pharmaceutically acceptable excipients. For example, a tablet may comprise at least one filler, e.g., lactose, ethylcellulose, microcrystalline cellulose, silicified microcrystalline cellulose; at least one disintegrant, e.g., cross-linked polyvinylpyrrolidinone; at least one binder, e.g., polyvinylpyridone, hydroxypropylmethyl cellulose; at least one surfactant, e.g., sodium laurylsulfate; at least one glidant, e.g., colloidal silicon dioxide; and at least one lubricant, e.g., magnesium stearate.
The pharmaceutical composition of the invention may be in the form of a sterile injectable aqueous or oleaginous suspension, which may be formulated according to the known art using suitable dispersing, wetting or suspending agents. The sterile injectable preparation may also be an injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Acceptable vehicles and solvents that may be employed include, without limiting, water, Ringer's solution, polyethylene glycol (PEG), 2- hydroxypropyl-P-cyclodextrin (HPCD), a surfactant such as Tween-80, and isotonic sodium chloride solution.
Pharmaceutical compositions according to the invention, when formulated for inhalation, may be in any suitable form, e.g., liquid or fine powder, and may be administered utilizing any suitable device known in the art, such as pressurized metered dose inhalers, liquid nebulizers, dry powder inhalers, sprayers, thermal vaporizers, electrohydrodynamic aerosolizers, and the like.
For instance, nebulizers use oxygen, compressed air or ultrasonic power to break up solutions and suspensions into small aerosol, i.e., a mixture of gas and solid or liquid particles, droplets that are inhaled from the mouthpiece of the device.
The pharmaceutical composition of the invention may be formulated for controlled release of one or more of the active agents, i.e., one or more of the cannabinoids and terpenes. Such compositions may be formulated as controlled-release matrix, e.g., as controlled- release matrix tablets in which the release of a soluble active agent is controlled by having the active diffuse through a gel formed after the swelling of a hydrophilic polymer brought into contact with dissolving liquid (in vitro) or gastro-intestinal fluid (in vivo). Many polymers have been described as capable of forming such gel, e.g., derivatives of cellulose, in particular the cellulose ethers such as hydroxypropyl cellulose, hydroxymethyl cellulose, methylcellulose or methyl hydroxypropyl cellulose, and among the different commercial grades of these ethers are those showing fairly high viscosity. In other configurations, the compositions comprise the active agent formulated for controlled release in microencapsulated dosage form, in which small droplets of the active agent are surrounded by a coating or a membrane to form particles in the range of a few micrometers to a few millimeters.
In another particular such aspect, the composition of the present invention as defined in any one of the embodiments above is in the form of a nutraceutical composition, i.e., the carrier comprised within said composition is a nutraceutically acceptable carrier, and may be formulated as a solid dosage form such as tablet, capsule, pill and powder, or as a liquid dosage form such as syrup and elixir, and may be prepared by conventional techniques known in the art. Particular such nutraceutical compositions are formulated as a food supplement (e.g., when comprising beeswax of honey as a carrier), drink or beverage.
The pharmaceutical or nutraceutical compositions of the invention are useful in treatment of ASD.
ASD encompasses a range of conditions classified as neurodevelopmental disorders in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, published in 2013). Individuals diagnosed with ASD must present two types of symptoms: deficits in social communication and social interaction; and restricted, repetitive patterns of behavior, interests or activities. The DSM-5 redefined the ASDs to encompass the previous (DSM-IV- TR (DSM text revision, published in 2000) diagnoses of autism, Asperger syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), and childhood disintegrative disorder. Features of these disorders include social deficits, communication difficulties, stereotyped or repetitive behaviors and interests, sensory issues, and in some cases, cognitive delays.
Autism may be categorized as either syndromic (secondary) or non-syndromic. The traditional definition of syndromic ASD refers to a condition caused by a well-known genetic variant, i.e., a disorder with a clinically defined pattern of somatic abnormalities and a neurobehavioral phenotype that may include ASD. Syndromic autisms, which are so defined because they occur in individuals with neurological disorders such as fragile X mental retardation, tuberous sclerosis, or Rett syndrome, harbor a set of phenotypes that can be fully attributed to a mutation in a particular gene or a set of genes.
Non-syndromic autism, which comprises a vast majority of autism cases, is not linked to other neurological diseases (or syndromes) and is caused by unknown genetic or environmental cause. Moreover, many genes involved in non-syndromic intellectual disabilities and in epilepsy have also been implicated in the etiology of non-syndromic ADS
(Ivanov et al., Autism spectrum disorder-a complex genetic disorder. Folia medica, 2015, 57, 19-28; Fernandez and Scherer. Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach. Dialogues in clinical neuroscience, 2017, 19, 353).
Symptoms of ASD include behavioral problems that may be internalizing problems such as being emotionally reactive, depressed/anxious affect, expressing somatic complaints and withdrawal, or externalizing problems such as aggression, defiance and inattentiveness, tantrums and self-injury. Additionally, symptoms include restrictive/repetitive behavior and deficit in social communication/interaction behaviors (https://www.autismspeaks.org/what- autism/symptoms).
In another aspect, the present invention thus relates to a method for treatment of ASD in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to any one of the embodiments above.
The term "subject" as used herein refers to any mammal, e.g., a human, non-human primate, horse, ferret, dog, cat, cow, and goat. In a preferred embodiment, the term "subject" denotes a human, i.e., an individual. In some embodiments, the subject is a child or adolescent.
The term "treatment" as used herein refers to the administering of a therapeutic amount of pharmaceutical composition as described above, which is effective to ameliorate undesired symptoms associated with said medical condition; prevent the manifestation of such symptoms before they occur; slow down the progression of said medical condition; slow down the deterioration of symptoms; enhance the onset of remission period; and/or lessen the severity of said medical condition.
The term "therapeutically effective amount" as used herein means an amount of said pharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought. The amount must be effective to achieve the desired therapeutic effect as described above, depending inter alia on the type and severity of the condition to be treated and the treatment regime. The effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the
person versed in the art will know how to properly conduct such trials to determine the effective amount. As generally known, an effective amount depends on a variety of factors including the affinity of the ligand to the receptor, its distribution profile within the body, a variety of pharmacological parameters such as half-life in the body, on undesired side effects, if any, on factors such as age and gender, etc.
In certain embodiments, the pharmaceutical composition according to any one of the embodiments above, administered according to the method of the invention is useful for reducing hyperactivity symptoms, reducing self-injury behavior, improving sleeping, and/or improving social communication in said subject.
Unless otherwise indicated, all numbers expressing, e.g., weight ratios of the cannabinoids and terpenes comprised within the composition of the invention as defined above, used in this specification are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification are approximations that may vary by up to plus or minus 10% depending upon the desired properties to be obtained by the present invention.
The following examples are presented in order to more fully illustrate some embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.
EXAMPLES
Study 1. Effects of medical cannabis-based treatment on children having ASD
Children with ASD exhibit co-morbid symptoms of hyperactivity, self-injury, aggressiveness, restlessness, anxiety and sleep disorders (Mannion and Leader, Comorbidity in autism spectrum disorder: A literature review. Research in Autism Spectrum Disorders, 2013, 12, 1595-1616; South and Jacqui, Sensory, emotional and cognitive contributions to anxiety in autism spectrum disorders. Frontiers in Human Neuroscience, 2017, 11, Article 20). Children with ASD are also known to suffer from susceptibility to flavors.
Previous studies have shown that a combination of CBD and THC at a weight ratio of 20: 1 has beneficial results in treating children with ASD as compared to CBD only. There is much experience in Israel with the treatment of autism using 20:1 CBD:THC products in more than 1000 children. The adverse effects of such products are familiar and they are temporary and not significant (Aran et al., Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems - A retrospective feasibility study. J. Autism. Dev. Disord., 2019, 49, 1284-1288).
Materials and methods
The present study utilized compositions each comprising a different combination of CBD and THC at a CBD:THC weight ratio of about 20:1; optionally a terpene combination comprising P-caryophyllene in an amount of about 70% of said terpene combination, linalool in an amount of about 20% of said terpene combination, a-pinene in an amount of up to 3% of said terpene combination, and limonene in an amount of up to 3% of said terpene combination; and MCT as a carrier oil. Each one of the various compositions was formulated as sublingual medicated drops each containing about 10 mg CBD and about 0.5 mg THC.
The study included four arms, each including five children at the age of 5-25 years old, diagnosed with ASD based on DSM IV (Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, 2000) or DSM V (Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, 2013) criteria, who were followed up for at least 30 days after commencement of treatment. Four ASD co-morbidity symptoms were evaluated: (a) hyperactivity symptoms (b) sleeping problems, (c) self-injury, and (d) social communication.
Patients in all arms were administered with a dose starting from 1 drop 4 times a day (i.e., about 40 mg CBD and 2 mg THC per 24 hour), which was increased, if necessary, up to 3 drops, 3 times a day, and 4 drops before sleep (i.e., about 130 mg CBD and about 6.5 mg THC per 24 hours).
Arm 1. Patients were treated with a composition comprising about 90% an extract obtained from Cannabis ZIV Sparkling Light (Israel Plant Breeders' Rights Application No.
4852/19; rich in CBD) and about 1.7% an extract obtained from Cannabis TIL Tachllta (Israel Plant Breeders' Rights Application No. 4837/19; rich in THC) and having CBD and THC in a ratio of about 20:1, respectively. The extractes were prepared by a cold wash ethanol extraction, more specifically by extracting (separating) the oil from a plant material of each one of the two species using cold ethanol (-20°C; 190 proof (95%)) as the solvent; evaporating the ethanol from the fraction thus obtained using a rotary evaporator; and distilling the crude extract obtained using a wiped-film evaporator (WFE; Pope Scientific Inc., USA). The HPLC analysis of the two extracts are shown in Table 1-2.
Arm 2. Patients were treated with a composition similar to that used in Arm 1, but further comprising about 2% by weight of the terpene combination referred to above.
Arm 3. Patients were treated with a composition based on a mixture of purified CBD and THC (rather than a mixture of two cannabis plant extracts, each containing components in addition to CBD and THC, as in the composition administered to the patients in Arm 1).
Arm 4. Patients were treated with a composition similar to that used in Arm 3, but further comprising about 2% by weight of the terpene combination referred to above. This composition is also referred to herein as Ait an Spectrum composition
Table 1. HPLC analysis of a ZIV Sparkling Light extract
“Based on weight of extract. The values represent the average of two analyses (one sample per strain; samples were analyzed in duplicates). nd - not determined
Table 2. HPLC analysis of the TIL Tachllta extract
“Based on weight of extract. The values represent the average of two analyses (one sample per strain; samples were analyzed in duplicates). nd - not determined
The content of cannabinoids (either a mixture of purified CBD and THC, or a mixture of the two extracts as CBD and THC sources) in each one of the various compositions used was about 20.1% by weight, and the content of the carrier oil (MCT) was either about 79.9% or about 77.9% by weight, depending on whether a terpene combination (2% by weight) was added or not.
The study was aimed at exploring the safety and efficacy of the compositions utilized, and testing their efficacy in treating children with ADS, more specifically in reducing, limiting, or attenuating each one of the co-morbid symptoms exhibited by these children. The compositions tested were orally administered to the children, according to the regimen described above, by their parents, who were also responsible for reporting the results based on their experience.
For each co-morbid symptom, the parents reported an improvement, no change, or worsening of symptoms, as compared to the baseline (i.e., the appearance of said symptom prior to the treatment). An overall change was defined based on the summation of all reports provided with respect to the children in each group. For all participating children, this was their first experience with CBD and no other cannabinoids were used before this study. During the first meeting, parents were instructed by an experienced authorized person how to administer the composition. Thereafter, a biweekly follow-up telephone interview was conducted with the parents, during which the parents were questioned regarding the status of the various ASD co-morbid symptoms exhibited by the particular kid (graded as improvement, no change, or worsening), emerging adverse effects, and medications that had been used during the study period.
Results and discussion
Fig. 1 shows the hyperactivity symptoms (e.g., how much calm the kid was, the rate of hyper events and duration thereof, and how easy was it to get the kid out of the event) in the participating kids. Fig. 2 shows the symptom of self-injury (e.g., self-harming, knocking the head in the wall, scratching the arms). Fig. 3 shows how much the sleeping problems (e.g., getting to sleep, waking at night, and disturbed sleeping) were improved
during the trial time. Fig. 4 shows the improvement in social communications (e.g., making eye contact with the caretaker, reaction to physical contact, pronouncing the needs in words or gestures) during the trial time. Fig. 5 shows the reaction to the taste of the medicine (the taste is a crucial element in children with ASD, since they are very sensitive to it, and in some cases, it prevents them from taking the medicine). The graph shows the improvement, according to the parents, in taking the medicine during the trial time. In all these figures, the Y axis shows the satisfaction level, and the X axis refers to the duration of testing. Fig. 6 shows the average of all the criterions tested in Figs. 1-5 (hyperactivity symptoms, selfinjury, sleeping problems, social communication, and flavor improvement) according to a parent’s report.
The results reported for the children of Arm 4 were the most significant, wherein said children demonstrated more presence, made eye contact more closely, and listened and learned more. Symptoms such as severe anger attacks, self-violence, and self-physical injuries, as well as violence in the surrounding, and long cries, faded and in some cases even disappeared.
In some of the children, but mainly and clearly in those of Arm 4, a substantial improvement in verbal capabilities was observed, and in some of the cases, treated children had started to talk for the first time.
The results presented herein, which are based on the reports provided by the parents of the children participating in the study, support previous publications suggesting that CBD, as well as CBD and THC combination at a weight ratio of 20:1, may be effective in improving co-morbid symptoms exhibited by children having ASD.
Yet, as surprisingly shown herein, a composition comprising a combination of purified CBD and THC in a weight ratio of about 20:1, and a terpene combination comprising P-caryophyllene, linalool, a-pinene and limonene in a particular weight ratio (Nitzan Spectrum composition), was significantly more effective in limiting or attenuating the co-morbid symptoms exhibited by said children than both a similar composition comprising a mixture of cannabis plant extracts as the CBD and THC sources, an a similar composition without said terpene combination, indicating that such a composition may be highly effective in treating children having ASD.
Furthermore, a product based on purified CBD and THC as exemplified herein was tastier than the corresponding product that is based on cannabis plant extracts as the CBD and THC sources; and the Nitzan Spectrum composition obtained after the addition of the terpene combination exemplified herein was superior to the product without the terpene combination, and had a better flavor.
Study 2: A phase III clinical trial designed to evaluate the safety and efficacy of Nitzan Spectrum on ASD pediatric population
Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Several studies are being conducted worldwide on cannabidiol use in ASD; however, these studies are still ongoing, and data on the effects of its use is very limited. The objective of this study was to report the experience of parents who administer, under supervision, oral cannabinoids to their children with ASD.
After obtaining a license from the Israeli Ministry of Health, parents of children with ASD were instructed how to administer oral drops of Nitzan Spectrum, medical cannabidiol oil. Information on comorbid symptoms and safety was prospectively recorded biweekly during follow-up interviews. An independent group of specialists analyzed these data for changes in ASD symptoms and drug safety.
Efficacy of treatment was tested using the Autism Diagnostic Observation Schedule (ADOS), 5 subtests of an age-appropriate Wechsler Intelligence Scale (WPPSI, WISC or WAIS), and the Vineland adaptive behaviors scale. All assessments were conducted before treatment initiation and again after 6 months. The ADOS was conducted by a trained and licensed speech therapist and cognitive testing was conducted by a licensed developmental psychologist. The Vineland was completed in a parent interview.
Study drug
All participants received Nitzan Spectrum, a medical cannabis extract infused in Medium-Chain Triglycerides (MCT) oil with a CBD:THC ratio of 20:1 for a period of six months. All participants started with one drop daily (each drop: 0.3mg THC and 5.7mg CBD) and increased gradually until improvement was reported by the parents. Final dose
did not exceed lOmg/kg/day (or total of 400mg per day) of CBD and 0.5mg/kg/day (or total of 20mg per day) of THC.
Method
Main inclusion criteria for the trial were -
ASD patients, 5-25 yo
Behavior problems, reported in last 6 months
Efficacy of treatment was tested using the Autism Diagnostic Observation Schedule (ADOS), 5 subtests of an age-appropriate Wechsler Intelligence Scale (WPPSI, WISC or WAIS), and the Vineland adaptive behaviors scale. All assessments were conducted before treatment initiation and again after 6 months. The ADOS was conducted by a trained and licensed speech therapist and cognitive testing was conducted by a licensed developmental psychologist. The Vineland was completed in a parent interview.
Cognitive assessments of children above the age of 6 years old included the Block design and Matrix subtests from the Perceptual Organization Index (POI), the Vocabulary and Similarities subtests from the Verbal Comprehension Index (VCI) and the Digit symbolcoding subtest from the Processing Speed Index (PSI). Children below the age of 6 years old preformed the Information subtest instead of the Similarities subtest.
Statistical analyses included paired T-tests to assess longitudinal changes in scores before and after treatment. Pearson correlation coefficients were used to assess relationships with age across scores of homological subscales.
Dosing
The average doses in the morning, noon, evening and the total for all day are presented in Table 3.
Safety Data
No abnormalities were observed during the trial.
Efficacy data
During the study the efficacy data was collected.
ADOS calibrated severity score (CSS) improved (decreased) significantly following treatment (M=-0.75, SD=1.24, t(31)=-3.41, p=0.002, Fig. 7). The total Vineland scores also improved (increased) significantly following treatment (M=5.46, SD=13, t(40)=2.69, p=0.01, Fig. 8). Improvements were apparent in the communication (M=5.65, SD=17.26, t(40)=2.1, p =0.042), daily living (M=6.05, SD=14.79, t(40)=2.62, p =0.012), and socialization (M=5.98, SD=15.19, t(40)=2.52, p=0.016) sub-scales. The Verbal Comprehension Index of the cognitive tests also improved significantly (M=0.65 SD=1.94, t(36)=2.04, p =0.048).
The efficacy data was collected also by validated ASD questionnaires and analyzed in order to demonstrate the efficacy of Nitzan Spectrum in ASD population. The data is presented in Fig. 9.
The data demonstrate a significant improvement in the communication and socialization skills of children administered with the herein disclosed Nitzan Spectrum composition, as demonstrated by the improvement in the ADOS calibrated severity score (CSS), the total Vineland scores and the Verbal Comprehension Index.
Importantly, a significantly life changing improvement in daily living and communication was reported by the parents whose kids were administered with the Nitzan Spectrum composition.
While certain embodiments of the invention have been illustrated and described, it will be clear that the invention is not limited to the embodiments described herein. Numerous modifications, changes, variations, substitutions and equivalents will be apparent to those skilled in the art without departing from the spirit and scope of the present invention as described by the claims, which follow.
Claims (25)
1. A composition comprising a cannabinoid combination, a terpene combination, and a carrier, wherein said cannabinoid combination comprising cannabidiol (CBD) or an enantiomer or diastereomer thereof, optionally partially or fully carboxylated at position 6’ thereof; wherein the terpene combination comprises at least three terpenes selected from P- caryophyllene, linalool, a-pinene and limonene, and wherein the terpene combination comprises about 3-30% by weight of said cannabinoid combination.
2. The composition of claim 1, wherein the CBD constitutes 5-30% by weight of the cannabinoid combination.
3. The composition of any one of claims 1-2, wherein the THC constitutes 0.08-3.0% by weight of the cannabinoid combination.
4. The composition of of any one of claims 1-3, wherein the CBD and the THC are present in a weight ratio of 20: 1.
5. The composition of any one of claims 1-4, wherein the terpene combination constitutes about 0.4-4.8% by weight of said composition.
6. The composition of any one of claims 1-4, wherein the cannabinoid combination further comprises A9-tetrahydrocannabinol (A9-THC) or an enantiomer or diastereomer thereof, optionally partially or fully carboxylated at position 2 thereof.
7. The composition of claim 6, wherein said cannabinoid combination consists of CBD and A9-THC.
8. The composition of any one of claims 1-7, wherein said cannabinoid combination comprises CBD in an amount of 5-27% by weight, and A9-THC in an amount of 0.01-2.5% by weight.
9. The composition of any one of claims 1-8, wherein said terpene combination comprises a-pinene, limonene, linalool, and P-caryophyllene.
10. The composition of any one of claims 1-8, wherein said terpene combination comprises P-caryophyllene, and at least two of a-pinene, limonene, and linalool.
36
11. The composition of claim 10, wherein the P-caryophyllene constitutes about 50-90% by weight of said terpene combination, the linalool, when present, constitutes about 10-30% by weight of said terpene combination; and each one of the a-pinene and limonene, when present, independently constitutes up to 5% by weight of said terpene combination.
12. The composition of claim 11, wherein said terpene combination comprises P- caryophyllene in an amount of about 70% of said terpene combination, linalool in an amount of about 20% of said terpene combination, a-pinene in an amount of up to 3% of said terpene combination, and limonene in an amount of up to 3% of said terpene combination.
13. The composition of any one of claims 1-12, wherein said carrier is beeswax, honey, or a carrier oil selected from a medium chain triglyceride (MCT), coconut oil, canola oil, olive oil, avocado oil, grapeseed oil, hempseed oil, sunflower oil, black seed oil, rosehip oil, argan oil, palm tree oil, and jojoba oil.
14. The composition of claim 13, wherein said carrier oil is an MCT.
15. The composition of any one of claims 1-14, further comprising at least one additional cannabinoid selected from cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), cannabidiphorol (CBDP), cannabidiol monomethyl ether (CBDM), cannabidiol-C4 (CBD- C4), cannabidiorcol (CBD-C1), A9-tetrahydrocannabivarin (A9-THCV), A9-THCVA, A8- THC, A8-THCA, A8-THCV, A8-THCVA, A9-tetrahydrocannabiphorol (A9-THCP), iso- tetrahydrocannabinol-type (iso-THC), cannabinol (CBN), cannabinolic acid (CBNA), cannabinol-C4 (CBN-C4), cannabinol-C2 (CBN-C2), cannabiorcol (CBN-C1), cannabinol methyl ether (CBNM), cannabinodiol (CBND), cannabigerol (CBG), cannabigero varin (CBGV), cannabigerolic acid (CBGA), cannabigerovarinic acid (CBGVA), cannabigerol monomethyl ether (CBGM), cannabigerolic acid monomethyl ether (CBGAM), cannabichromene (CBC), cannabichromenic acid (CBCA), cannabichromevarin (CBCV), cannabichromevarinic acid (CBCVA), cannabichromanon (CBCN), cannabicyclol (CBL), cannabicyclolic acid (CBLA), cannabicyclovarin (CBLV), cannabivarin (CBV), cannabivarinic acid (CBVA), cannabielsoin (CBE), cannabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabitriol (CBT), cannabitriolvarin (CBTV), ethoxy- cannabitiolvarin (CBTVE), cannabifuran (CBF), dehydrocannabifuran (DCBF), cannabiripsol (CBR), or an enantiomer, diastereomer, racemate, or a salt thereof.
37
16. The composition of claim 15, wherein the at least one additional cannabinoid constitutes up to 5% by weight of the composition.
17. The composition of any one of claims 1-16, formulated as an emulsion.
18. The composition of any one of claims 1-17, wherein at least one of the CBD, the THC, the P-caryophyllene, the linalool, the a-pinene or the limonene is in a form of synthetic, purified, extracted or isolated molecules.
19. A pharmaceutical or nutraceutical composition according to any one of claims 1-18.
20. The pharmaceutical composition of claim 19, formulated for oral, buccal or sublingual administration, or for inhalation.
21. The pharmaceutical composition of claim 19, formulated as a liquid dosage form such as a solution, syrup and elixir; or as a solid dosage form such as a tablet, capsule, and pill.
22. The nutraceutical composition of claim 19, formulated as a food supplement, drink or beverage.
23. The pharmaceutical or nutraceutical composition of any one of claims 19-22, for treatment of autism spectrum disorder (ASD).
24. A method for treatment of autism spectrum disorder (ASD) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to any one of claims 19-23.
25. The method of claim 24, for reducing hyperactivity symptoms, reducing self-injury behavior, improving sleeping, and/or improving social communication in said subject.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063107337P | 2020-10-29 | 2020-10-29 | |
US63/107,337 | 2020-10-29 | ||
PCT/IL2021/051254 WO2022091080A1 (en) | 2020-10-29 | 2021-10-24 | Compositions and methods for treatment of autism spectrum disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021369942A1 true AU2021369942A1 (en) | 2023-06-15 |
Family
ID=81383680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021369942A Pending AU2021369942A1 (en) | 2020-10-29 | 2021-10-24 | Compositions and methods for treatment of autism spectrum disorder |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2021369942A1 (en) |
IL (1) | IL302392A (en) |
WO (1) | WO2022091080A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3227884A1 (en) | 2021-08-04 | 2023-02-09 | John Crawford | Cannabinoid derivatives and their use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3917505A4 (en) * | 2019-01-29 | 2022-11-02 | Buzzelet Development And Technologies Ltd | Terpene-enriched cannabinoid composition and method of treatment for treating conditions and/or symptoms associated with autism spectrum disorder |
-
2021
- 2021-10-24 WO PCT/IL2021/051254 patent/WO2022091080A1/en active Application Filing
- 2021-10-24 AU AU2021369942A patent/AU2021369942A1/en active Pending
- 2021-10-24 IL IL302392A patent/IL302392A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL302392A (en) | 2023-06-01 |
WO2022091080A1 (en) | 2022-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11529320B2 (en) | Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use | |
AU2019297198B2 (en) | Composition and method for treating pain | |
US10751380B2 (en) | Compound and method for treating spasms, inflammation and pain | |
KR20190029660A (en) | High-intensity oral cannabinoid dosage form | |
WO2020188551A1 (en) | Methods and compositions for treating autism spectrum disorder and associated disorders | |
JP2022075675A (en) | Compositions containing tannic acids and uses thereof | |
BR112019026877A2 (en) | sleep disorder compositions and treatments | |
WO2006034187A2 (en) | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity | |
JP2023001138A (en) | Novel cannabinoid compositions and methods of use | |
US20210275618A1 (en) | Method for obtaining an extract of a plant biomass | |
US20160317466A1 (en) | Compositions comprising terpene compounds for treating negative sensory phenomena | |
WO2019159176A1 (en) | Compositions and methods for treatment of neurodegenerative diseases | |
EP3817734A1 (en) | Composition and method for opioid sparing | |
AU2021369942A1 (en) | Compositions and methods for treatment of autism spectrum disorder | |
WO2020183455A1 (en) | Cannabinoid combinations for treating low back pain | |
WO2022115796A1 (en) | Compositions and methods for treating neurological conditions | |
WO2020183456A1 (en) | Cannabinoid combinations for treating chronic pain in dialysis patients | |
JP2019516791A (en) | Phenolic compounds for the treatment of central nervous system and vasculature disorders and their combination with benzodiazepine fused to 1,4-dihydropyridine | |
WO2019175290A1 (en) | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence | |
US20240009132A1 (en) | Cannabinoids in the treatment of autism spectrum disorder | |
AU2021215262A1 (en) | Composition and method for treating chronic pain | |
WO2020188569A1 (en) | Methods and compositions for preventing or treating weight gain caused by psychiatric drugs | |
AU2021106137B4 (en) | Composition and method for treating chronic pain | |
WO2023060323A1 (en) | Terpene-containing formulations and use thereof | |
US10842772B1 (en) | Cannabis-based bioactive formulations and methods for use thereof |